secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pasithea Therapeutics Corp. (KTTA)
CIK:        0001841330
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001213900-25-040725
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pasithea closes $5M public offering, receives $1.3M from warrant exercises
--------------------------------------------------------------------------

- Offered 3,571,428 units at $1.40/unit (common stock or pre-funded warrant + Series C/D warrants); gross $5M.
- Additional $1.3M from exercise of 914,286 Series D warrants at closing; total gross proceeds $6.3M.
- Net proceeds ~$4.3M after fees and expenses; intended for R&D, clinical trials, and general corporate.
- H.C. Wainwright acted as exclusive placement agent; 7% cash fee plus warrants for 250,000 shares at $1.75.
- 90-day lockup on further equity issuance; one-year restriction on variable rate transactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841330/000121390025040725/0001213900-25-040725-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841330/000121390025040725/ea0241313-8k_pasithea.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-040725

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer